Why It Moved
Deep dives into the technical and fundamental catalysts driving major security movements across the Indian markets.
Why MTAR Technologies shares fell 4% today? Explained
MTAR Technologies shares fell over 4% after concerns emerged regarding operational issues at a major Bloom Energy-linked data center project. Investors are monitoring the impact on future order visibility and execution.
Why NLC India shares are down over 3% today
Shares of NLC India fell over 3% on Tuesday, June 9 , after the Government of India announced an Offer for Sale (OFS) to divest up to a 3% stake in the state-run company. The stock declined to around Rs 324 even though the company continues to report strong operational performance. The primary reason behind the fall is the OFS pricing and the increase in near-term share supply. What is weighing on the stock? The government has fixed the OFS floor price at Rs 303 per share , which represents a discount of nearly 10% to Monday's closing price of Rs 335.75 . Whenever a large shareholder, especially the government, offers shares at a discount through an OFS, market participants often adjust the stock price lower toward the offer price. This creates short-term selling pressure as investors anticipate additional supply entering the market. Details of the OFS Under the transaction, the government will initially sell a 2% stake , equivalent to about 2.78 crore shares . An additional 1% green shoe option can be exercised if demand remains strong, taking the total offer size to nearly 4.16 crore shares . The OFS opens for institutional investors on June 9 , while retail investors can bid on June 10 . Is the fall linked to business performance? No. The decline is largely technical and supply-driven rather than related to any deterioration in NLC India's operations or earnings outlook. In fact, the government highlighted NLC India's strong operational and financial performance, consistent shareholder returns, and dividend track record while announcing the stake sale. Market view Stocks often face pressure during OFS announcements because: The offer price is usually below the prevailing market price. Additional share supply enters the market. Some investors wait to participate in the OFS rather than buy from the secondary market. As a result, NLC India's decline today appears to be primarily driven by the government's stake sale announcement rather than any negative company-specific development.
Consumer stocks remain under pressure; Investec prefers Varun Beverages, Marico, Titan and Eternal
Consumer sector stocks witnessed a broad correction over the past month, but brokerage Investec remains selectively positive on companies with strong brands, pricing power and premiumisation-led growth opportunities. In its latest consumer sector note dated June 8, Investec highlighted that FMCG companies continued to take price hikes across several categories, including snacks, breads, edible oils, soaps and oral care products. The brokerage noted that companies are using selective pricing actions to offset persistent cost pressures from key raw materials. Investec pointed out that inflationary pressures remain visible in commodities such as edible oils, tea, crude-linked inputs, polymers and gold, while trends in other raw materials have been relatively mixed. The brokerage also observed a shift in strategy among quick-service restaurant (QSR) operators. Companies have increasingly focused on value resets, combo recalibration and menu rationalisation to maintain customer traffic amid a price-sensitive consumption environment. Despite the recent correction across consumer stocks, Investec believes select companies remain well-positioned to navigate the current environment. Among large-cap names, the brokerage's preferred picks are Eternal, Marico, Varun Beverages and Titan Company. In the mid-cap segment, Investec continues to favour United Spirits and Radico Khaitan, citing ongoing premiumisation trends in the alcoholic beverages market. For the small-cap space, the brokerage's preferred names are Mrs Bector Food Specialities and International Gemmological Institute. According to Investec, companies with strong distribution networks, resilient demand, pricing flexibility and exposure to premium consumption trends are likely to outperform as the sector navigates inflationary pressures and evolving consumer spending patterns. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Why are Hitachi Energy shares up over 2% today? Explained
Shares of Hitachi Energy India gained more than 2% in early trade on Thursday, June 4, after global brokerage Citi initiated coverage on the stock with a "Buy" rating and a target price of Rs 46,700 per share. The brokerage's positive outlook is driven by expectations of a significant long-term investment cycle in transmission and distribution (T&D) infrastructure, both in India and across global markets. Citi believes power grids are becoming one of the biggest bottlenecks in the global energy transition, creating substantial opportunities for companies involved in grid modernization and power transmission equipment. According to estimates cited by Citi from BloombergNEF (BNEF), global transmission and distribution capital expenditure could reach nearly $15 trillion between 2025 and 2050. The spending is expected to be supported by rising renewable energy adoption, increasing power demand from data centres, and continued industrial expansion. The brokerage highlighted that India is well-positioned to benefit from this trend due to its strong manufacturing capabilities in transmission and distribution equipment. India currently produces nearly 80% of the world's transmission and distribution products, making it a key supplier to both domestic and export markets. Citi also pointed to several structural growth drivers for the sector, including the rapid adoption of High Voltage Direct Current (HVDC) technology, government policies promoting localization, and growing export opportunities for Indian manufacturers. Against this backdrop, Citi initiated coverage on Hitachi Energy India with a Buy rating and a target price of Rs 46,700, reflecting confidence in the company's ability to benefit from increasing investments in grid infrastructure and power transmission projects. The brokerage believes the company's technology portfolio, market position and exposure to grid modernization projects place it in a strong position to capitalize on the expanding opportunities in India's power sector. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Why are GE Vernova T&D India shares up over 2% today? Explained
Shares of GE Vernova T&D India surged more than 2% in early trade on Thursday, June 4, after global brokerage Citi initiated coverage on the stock with a "Buy" rating and a target price of Rs 6,200 per share. The brokerage's bullish stance comes amid growing optimism around India's transmission and distribution (T&D) sector, which is expected to play a critical role in supporting the global energy transition and expanding renewable energy infrastructure. As of 9:31 AM, GE Vernova T&D India shares were trading near their day's high after opening at Rs 5,134. The stock touched an intraday high of Rs 5,148.50 and a low of Rs 5,036.50, compared to its previous close of Rs 4,964.50. Trading activity remained strong, with around 1.82 lakh shares changing hands. Citi noted that power grids are increasingly becoming a major bottleneck in the transition towards cleaner energy systems. As renewable energy installations rise globally, significant investments will be required to strengthen transmission networks and ensure reliable electricity delivery. According to estimates cited by the brokerage from BloombergNEF (BNEF), global transmission and distribution capital expenditure could reach nearly $15 trillion between 2025 and 2050. The investment cycle is expected to be driven by rising renewable energy penetration, expanding data centre infrastructure and growing industrial demand. The brokerage believes India is well-positioned to benefit from this trend, highlighting that the country currently manufactures around 80% of the world's transmission and distribution products. This gives Indian companies a strong position in both domestic and export markets. Citi also highlighted several long-term growth drivers for the sector, including increasing adoption of High Voltage Direct Current (HVDC) technology, government-led localisation initiatives and growing export opportunities. The positive brokerage initiation further boosted investor sentiment towards GE Vernova T&D India, which has already delivered a strong rally over the past year and is currently trading close to its 52-week high of Rs 5,222.10. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Why are Rajesh Exports shares locked in 5% lower circuit today? Explained
Shares of Rajesh Exports hit the 5% lower circuit on Thursday, June 4, after the Securities and Exchange Board of India (SEBI) initiated an investigation into the company and its Executive Chairman Rajesh Mehta over alleged financial misrepresentation and disclosure-related violations. The stock fell to Rs 103.92, down 4.99%, after the market reacted to SEBI's interim order, which alleged that the company may have misrepresented financial statements involving transactions aggregating around Rs 15 lakh crore during FY21 to FY25. According to the regulator, the amount represented nearly 99.8% of the company’s consolidated revenue reported during the period. SEBI has also restrained Executive Chairman Rajesh Mehta from dealing in the company’s securities until further orders. The regulator cited multiple alleged violations, including non-disclosure of material financial information, unavailability of subsidiary financial statements, misrepresentation in annual reports, a false claim regarding investment in a gold mine in Africa, and lack of cooperation during the investigation. According to the interim order, SEBI's preliminary findings indicated that derivatives transactions undertaken by Rajesh Mehta were allegedly recorded in the company’s books as corporate transactions. The regulator also alleged incorrect accounting treatment of foreign exchange fluctuations and raised concerns regarding adjustments made to long-outstanding trade receivables. SEBI further stated that Rajesh Exports did not provide complete access to financial records and information related to overseas subsidiaries, which allegedly hampered the investigation process. The regulator observed that the company's conduct prima facie indicated a pattern of financial misrepresentation, concealment and regulatory non-compliance across multiple financial years. SEBI added that investors may have been presented with an inflated picture of the company's operational scale and financial position. The sharp fall in the stock reflects investor concerns over the regulatory action and the potential implications of the ongoing investigation. Despite closing nearly 3% higher in the previous session, Rajesh Exports shares have declined more than 38% in 2026 so far and have lost nearly 80% of their value over the last five years. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
JBM Auto shares jump 10% in two sessions as electric bus leadership and Delhi-NCR EV push boost sentiment
Shares of JBM Auto extended their rally for a second consecutive session on Thursday, June 4, gaining over 6% to Rs 711.95. The stock has now surged more than 10% in the last two trading sessions as investors cheered the company’s leadership in India’s electric bus segment and the government's push towards electric commercial vehicles. The latest trigger came after JBM Auto announced that it emerged as the leading player in India’s electric bus market during May 2026, securing a 49% market share based on Vahan portal data. The company registered 157 electric buses during the month, the highest among all industry participants. JBM Auto said it has retained its leadership position in electric bus registrations after recording the highest registrations during FY26. The company also highlighted that the inclusion of Telangana vehicle registration data into the Vahan portal has provided a broader view of electric bus adoption across India. The rally follows Wednesday’s gains, when the stock surged after the Union Cabinet approved a Rs 5,041 crore scheme aimed at phasing out BS-IV trucks and buses in Delhi-NCR and replacing them with BS-VI and electric commercial vehicles. The scheme is expected to create fresh demand for electric buses and expand the addressable market for manufacturers like JBM Auto. The company currently operates what it describes as the world's largest dedicated integrated electric bus manufacturing facility outside China, located in the NCR region, with an annual production capacity of 20,000 electric buses. JBM Auto also stated that its electric buses have collectively covered over 400 million e-kilometres, transported more than one billion passengers and helped reduce over one billion kilograms of carbon dioxide emissions. At the time of writing, JBM Auto shares were trading at Rs 711.95, up 6.38% for the day, taking the two-session gain to over 10%. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Gujarat Gas shares jump 6% as Jefferies upgrades stock; Nomura sees further upside
Gujarat Gas shares were in focus on Tuesday, June 2, rising more than 6% in early trade after positive commentary from global brokerages Jefferies and Nomura. The stock climbed to an intraday high of ₹423.90 and was trading around ₹422, compared with its previous close of ₹396.80. Jefferies upgraded Gujarat Gas to Hold and assigned a target price of ₹415 per share , following a stronger-than-expected operational performance. According to the brokerage, the company delivered a beat on both volumes and margins, supported by favourable developments in its key Morbi market. The brokerage highlighted that the non-availability of propane in Morbi has helped Gujarat Gas gain market share, resulting in higher volumes and margin expansion. Jefferies also incorporated the company’s gas trading business into its financial model following the completion of the amalgamation process. Reflecting the improved outlook, Jefferies raised its city gas distribution (CGD) EBITDA estimates by 45% for FY27, citing robust demand from Morbi and sustained operational momentum. Nomura, meanwhile, maintained its Buy rating on Gujarat Gas with a target price of ₹511 per share , implying significant upside from current levels. The brokerage said the outlook for the CGD business remains strong, while the gas trading segment is expected to remain stable. It also sees meaningful value unlocking from the amalgamation and expects Morbi volumes to remain a key earnings driver in the near term. Nomura noted that management has guided for a CGD EBITDA margin of ₹5.5–6.5 per standard cubic metre (scm). The brokerage has factored in EBITDA margins of ₹3.2/scm for FY27 and ₹5.4/scm for FY28, reflecting expectations of continued improvement in profitability. The positive brokerage commentary comes at a time when investors are closely tracking demand trends in industrial gas consumption, particularly in Morbi, one of the country’s largest ceramic manufacturing hubs. Higher industrial volumes and benefits from the newly integrated gas trading business are expected to remain key drivers for Gujarat Gas going forward. At the time of writing, Gujarat Gas was among the top gainers in the city gas distribution space, outperforming the broader market. Disclaimer The views and recommendations mentioned are those of the respective brokerages and do not represent the views of this publication. This article is for informational purposes only and should not be construed as investment advice.
NHPC stock under pressure after Centre announces 6% stake sale through OFS
NHPC shares slipped over 3% after the Government of India announced an Offer for Sale (OFS) with a floor price of ₹71 per share and a base issue size of 3% equity.
Supriya Lifescience shares jump 16% after strong Q4 results; management reiterates FY27 revenue target
Supriya Lifescience shares surged over 16% after reporting strong Q4 FY26 results, with revenue rising 50% YoY and profit increasing 47%.
Here’s why MCX shares fell sharply 4% in trade today
MCX shares declined nearly 4% after UBS downgraded the stock to Neutral, saying strong volume growth and earnings momentum are already reflected in valuations.
Wockhardt gains 7% to hit fresh 52-week high as India approves first-in-class antibiotic Zaynich
Wockhardt shares gained nearly 7% after CDSCO granted marketing authorisation for Zaynich, the company’s first-in-class antibiotic for complicated urinary tract infections.
Why are Delta Corp shares down 12% today? Supreme Court GST verdict rattles gaming stocks
Shares of Delta Corp Ltd came under heavy selling pressure on Friday, falling more than 12% in early trade after the Supreme Court upheld the constitutional validity of the retrospective 28% Goods and Services Tax (GST) levy on online gaming companies, fantasy sports platforms and casinos. The stock was trading at ₹71.10 on the NSE at around 9:30 AM, down 12.3% from its previous close of ₹81.05. Delta Corp touched an intraday low of ₹68.15, while trading volumes crossed 1.16 crore shares in the opening session. The Supreme Court, in its ruling delivered on May 27, upheld GST authorities’ decision to levy 28% tax on the full face value of bets placed in online gaming activities. The apex court also validated retrospective tax demands, delivering a major setback to the real-money gaming industry. According to reports, the verdict effectively revives tax demands worth nearly ₹2.5 lakh crore across the gaming ecosystem, including online gaming companies, fantasy sports platforms and casino operators. The court observed that online gaming activities involving staking money on uncertain outcomes would qualify as betting and gambling under the GST framework, making them liable for the higher tax rate. The ruling has intensified concerns over the financial impact on companies operating in the gaming and casino space. Industry estimates suggest the sector faces enormous retrospective tax exposure, with authorities expected to continue pursuing recovery proceedings following the judgment. Delta Corp has been among the companies facing GST-related scrutiny in recent years. The company had previously received a GST show-cause notice of ₹23,204 crore as part of the broader tax dispute involving the gaming sector. Market participants appear to be reacting to the possibility that the judgment could prolong legal and financial uncertainty for gaming companies, even as the industry evaluates potential next steps after the Supreme Court’s decision. Meanwhile, Delta Corp shares were trading 12.3% lower at ₹71.10 on the NSE at the time of publishing this article, compared with the previous close of ₹81.05. Disclaimer: This article is for informational purposes only and should not be construed as investment advice. Investors should consult qualified financial advisers before making investment decisions.
Bharat Dynamics shares slide 6% on weak Q4 and a slew of downgrades by analysts
Bharat Dynamics shares opened nearly 6% lower after weak Q4 results prompted Goldman Sachs and Motilal Oswal to downgrade the stock and cut target prices.
AIA Engineering shares surge 8% intraday as Q4 profit jumps 38%, margins improve
AIA Engineering shares surged after Q4 FY26 profit rose 38% YoY to ₹393 crore, while margins improved and revenue grew.
Delta Corp shares rally 12% ahead of Supreme Court verdict on online gaming laws
Delta Corp shares rallied over 12% as investors tracked the Supreme Court verdict on online gaming laws and stake-based games.
Weak Q4 results with profit falling 24% weighs on Transrail Lighting stock
Transrail Lighting shares dropped nearly 6% after weak Q4 earnings despite strong FY26 growth and a robust order book.
Here’s what sent Carraro India shares flying by 6% today
Carraro India shares gained 6% intraday after Q4 PAT jumped 73% and revenue rose sharply, supported by strong FY26 growth.
AEQUS shares fall nearly 8% after Q4 loss, margins shrink sharply
AEQUS shares dropped nearly 8% after the company reported a Q4 loss and sharp margin contraction despite strong revenue growth.
ONGC drops over 3% as Q4 earnings miss analyst estimates, production concerns weigh
ONGC shares fell over 3% after Q4 earnings missed analyst estimates, while Macquarie retained outperform with a ₹300 target price.
Coal India shares fall nearly 5% after government launches OFS at 10% discount
Coal India shares fell nearly 5% after the government launched an OFS with a floor price of ₹412 per share at a discount to market price.
Marksans Pharma shares surge 8% after strong Q4 earnings and margin expansion
Shares of Marksans Pharma Ltd surged around 8% on May 26 after the company reported a strong set of Q4FY26 earnings, driven by healthy revenue growth and sharp margin expansion. The stock was trading at ₹235.71, up 7.01% at around 1:01 PM, after touching an intraday high of ₹238.90 on the NSE. Trading volumes also remained strong following the earnings announcement. For the quarter ended March 2026, the company reported consolidated revenue from operations of ₹856.11 crore, compared with ₹708.46 crore in the corresponding quarter last year. Based on the reported financials, EBITDA for Q4FY26 stood at ₹195.42 crore against ₹126.94 crore in Q4FY25. EBITDA margin expanded significantly to 22.8% from 17.9% a year ago. Profit after tax for the quarter rose sharply to ₹149.03 crore from ₹90.73 crore reported in the corresponding period last year. Total income during the quarter increased to ₹891.29 crore from ₹723.80 crore in Q4FY25, while profit before tax climbed to ₹200 crore from ₹116.09 crore a year earlier. Sequentially too, the company reported improvement in performance. Revenue from operations rose from ₹754.43 crore in Q3FY26 to ₹856.11 crore in Q4FY26, while PAT increased from ₹113.69 crore to ₹149.03 crore. The company also reported total comprehensive income of ₹202.97 crore during the quarter compared with ₹117.21 crore in the year-ago period, aided by foreign currency translation gains. Market participants appeared to react positively to the strong profitability growth and margin expansion, helping the stock outperform broader market moves during the session. At the current market price, the stock remains below its 52-week high of ₹270.70, while comfortably above its 52-week low of ₹155. Disclaimer: This article is based on company filings and market data. Investors are advised to consult certified financial advisors before making investment decisions.
Astra Microwave shares surge 5% after Q4 profit jumps 44%, margin expands to 33.3%
Astra Microwave shares rose 5% after the company reported a 44% YoY jump in Q4 profit and announced a dividend of ₹2.40 per share.
Tejas Networks shares rally 6% as reports suggest Tata Sons will present future plans for company at meet today
Tejas Networks shares rallied nearly 6% in early trade on May 26 after an exclusive report by CNBC-TV18, citing sources, said Tata Sons’ board meeting scheduled for today is likely to discuss future business plans for several Tata Group companies, including Tejas Networks. The stock was trading at ₹501.9 apiece on the NSE, up around 6% at the time of publishing. Tejas Networks touched an intraday high of ₹503.3 during the session. According to the CNBC-TV18 report, Tata Sons chairman N Chandrasekaran and company leaders are expected to present business plans for five Tata Group entities, including Air India, Tata Digital, EV infrastructure venture Agastya, Tejas Networks and others. The report also said issues raised by Noel Tata in the previous board meeting are likely to be discussed. The report further noted that the Tata Sons listing issue may also come up for discussion, though the board remains divided on the matter. Sources told CNBC-TV18 that some members, including Venu Srinivasan, have spoken in favour of listing, while certain Tata veterans have expressed concerns that listing could alter the group’s long-standing ethos and values. For Tejas Networks, the discussion around future business plans is being seen positively by investors as it could indicate greater strategic focus and potential investments in the telecom and networking business. The company has been a key Tata Group bet in telecom infrastructure and 5G-related opportunities, particularly after Tata Sons-backed Tata Communications chairman Ganesh Lakshminarayanan also became chairman of Tejas Networks earlier this year. Investor sentiment around Tejas Networks has remained sensitive to developments linked to Tata Group’s telecom and digital ambitions, with markets closely tracking any commentary related to expansion plans, capital allocation and execution roadmap. Disclaimer: This article is for informational purposes only and should not be construed as investment advice.
Bliss GVS shares surge 15%, extend 2-day rally to over 20% after Anupam Rasayan acquisition deal
Bliss GVS Pharma shares surged nearly 15% in early trade on May 26, extending their two-day rally to more than 20%, after specialty chemicals maker Anupam Rasayan announced plans to acquire a controlling stake in the company and launch an open offer for public shareholders. The stock was trading at ₹364.9 on the NSE at the time of publishing this article, hitting a fresh 52-week high during the session. The sharp rally comes after Anupam Rasayan signed a definitive agreement to acquire a 43.3% stake in Bliss GVS Pharma for around ₹1,369.5 crore at ₹299 per share. The acquisition also triggered a mandatory open offer for an additional 26% stake from public shareholders at the same price of ₹299 per share, in line with SEBI takeover regulations. Reports suggest that Anupam Rasayan may eventually acquire up to 74.2% stake in Bliss GVS Pharma through the combination of the share purchase agreement, open offer and additional call option arrangements. Under the deal structure, Anupam Rasayan will acquire 4.58 crore equity shares representing 43.3% stake in Bliss GVS Pharma. The company also holds an option to acquire an additional 4.9% stake from existing shareholders. The Street is viewing the transaction positively as the acquisition would help Anupam Rasayan strengthen its presence across the pharmaceutical value chain. Analysts believe the deal could create an integrated life sciences and specialty pharma platform by combining Anupam Rasayan’s specialty chemicals capabilities with Bliss GVS Pharma’s formulations business. Bliss GVS Pharma is engaged in manufacturing and exporting pharmaceutical formulations including suppositories, tablets, capsules and injectables, with a strong presence in global markets, particularly in Africa and emerging economies. The open offer and change in control expectations have significantly boosted investor sentiment around the stock over the last two trading sessions. Disclaimer: This article is for informational purposes only and should not be construed as investment advice.
Here’s what the street liked about Blue Jet Healthcare’s Q4 results; Stock surges 6%
Blue Jet Healthcare shares rallied over 6% in early trade on May 26 after the company reported a sequentially strong Q4FY26 performance and received positive commentary from brokerage firm Emkay. The stock was trading at ₹511.85 on the NSE at the time of publishing this article. Brokerage firm Emkay maintained its ‘Reduce’ rating on the stock but raised the target price to ₹450 from ₹400 following the Q4 results. The brokerage noted that Blue Jet Healthcare’s Q4FY26 EBITDA came in nearly 20% ahead of estimates, supported by a sharp uptick in contrast media intermediate (CMI) sales and higher gross margins. Emkay also said CMI sales are expected to remain well ahead of expectations in FY27, while pharma intermediates business could see a sharp recovery during the year. The brokerage, however, maintained a cautious stance due to volatility in both core business segments, though it raised FY27E and FY28E EPS estimates by around 12% and 7% respectively. Blue Jet Healthcare reported a strong sequential recovery in profitability during Q4FY26. Revenue stood at ₹235 crore, up 21.96% quarter-on-quarter from ₹192 crore. EBITDA rose nearly 52% QoQ to ₹71 crore compared to ₹47 crore in the previous quarter, while EBITDA margin improved sharply to 30.37% from 24.37%, an expansion of around 600 basis points. Profit after tax (PAT) also increased 60.2% sequentially to ₹64 crore against ₹40 crore in Q3FY26. Earnings per share (EPS) came in at ₹3.71 versus ₹2.32 in the previous quarter. On a year-on-year basis, however, the company’s performance remained under pressure. Revenue declined 31.07% YoY from ₹340 crore, while EBITDA fell 49.08% YoY from ₹140 crore. PAT dropped 41.56% compared to ₹110 crore in Q4FY25. For the full FY26, Blue Jet Healthcare reported revenue of ₹947 crore, down 8.03% YoY. EBITDA for the year stood at ₹294 crore, declining 22.14%, while PAT fell 18.8% to ₹247 crore. Disclaimer: This article is for informational purposes only and should not be construed as investment advice.
Premier Energies shares rally 3% after these funds buy stake via block deal
Premier Energies shares gained nearly 3% in early trade on May 26 after several institutional investors, including Quant Mutual Fund and Nomura India, picked up stake in the company through a large block deal worth around ₹2,291 crore. The stock was trading higher at ₹1,013 on the NSE at the time of publishing this article. According to block deal data, the promoter group sold around 2.4 crore shares, representing nearly 5.3% equity stake, at an average price of ₹955 per share. Among the key buyers, Quant Mutual Fund purchased around 40.84 lakh shares worth nearly ₹390 crore, while Nomura India acquired 25 lakh shares valued at approximately ₹239 crore. Smallcap World Fund and Edelweiss Mutual Fund also bought 24.4 lakh shares and 20.9 lakh shares respectively. Other institutional buyers in the transaction included The Beekeeper Capital, Canara Robeco Mutual Fund and Tata Mutual Fund, among others. The block deal comes shortly after Premier Energies reported strong operational performance and continues to attract investor interest amid optimism around India’s renewable energy and solar manufacturing space. As reported earlier, the company has been benefiting from robust demand trends in the solar segment, while policy support for domestic manufacturing and clean energy transition remains a key long-term growth trigger for the sector. Disclaimer: This article is for informational purposes only and should not be construed as investment advice.
RVNL shares decline 3% after weak Q4 earnings, EBITDA margin slips to 4%
RVNL shares opened nearly 3% lower after the company reported a sharp decline in Q4 profit and EBITDA margin contraction.
Why is Titagarh Rail share price up 10% in trade today? Explained
Titagarh Rail shares rallied nearly 10% after reports suggested Indian Railways may float a ₹40,000 crore tender for 1 lakh wagons.
Yatharth Hospital shares fall 5%: What the Street disliked despite strong Q4FY26 growth
Yatharth Hospital & Trauma Care Services shares fell over 5% on May 25 despite reporting strong double-digit growth in revenue and profit for the March quarter, suggesting investors were concerned about profitability trends and the company’s aggressive expansion-led cost build-up. The stock was trading at ₹818.6, down 5.05%, after touching an intraday low of ₹792.85 on the NSE. The company reported consolidated revenue from operations of ₹341.56 crore for Q4FY26, up sharply from ₹233.03 crore in the corresponding quarter last year. Profit after tax rose to ₹44.70 crore from ₹38.72 crore YoY. However, beneath the headline growth numbers, several pressure points appear to have disappointed the Street. One of the biggest concerns was margin compression. While revenue jumped nearly 47% YoY, operating costs surged at a faster pace due to expansion of new hospitals and ramp-up expenses. Employee benefit expenses climbed to ₹70.10 crore in Q4FY26 versus ₹43.82 crore a year ago, while depreciation and amortisation expenses more than doubled to ₹30 crore from ₹12.87 crore. Other expenses also increased sharply to ₹129.38 crore from ₹86.54 crore. This meant profit growth failed to keep pace with revenue growth. EBITDA margins weakened despite strong occupancy and expansion-led scale-up, which investors may have interpreted as early signs of near-term pressure from aggressive capacity additions. Sequentially too, profitability softened. Profit before tax declined to ₹51.95 crore in Q4FY26 from ₹57.10 crore in Q3FY26 even as revenue increased. This suggests operating leverage is yet to fully emerge from newly commissioned hospitals. Investors also appear cautious about the company’s rapid expansion cycle. During FY26, Yatharth operationalised: A 300-bed hospital in Model Town, Delhi A 400-bed hospital in Faridabad A 150-bed hospital in Agra, expandable to 250 beds. Additionally, the company disclosed that one of its subsidiaries has entered into a binding term sheet to acquire an under-construction 250-bed hospital in Gurugram. While these expansions strengthen long-term growth visibility, the market may be factoring in: Longer gestation periods Initial occupancy ramp-up risks Margin dilution from underutilised assets Higher depreciation and finance costs in the near term Another factor that may have weighed on sentiment was the sharp increase in total assets and ongoing capex intensity. Consolidated assets expanded to ₹2,281.53 crore as of March 31, 2026, from ₹1,731.17 crore a year earlier. Meanwhile, the company reported investing cash outflows of nearly ₹598 crore during FY26, largely linked to expansion and acquisitions. Cash and cash equivalents also declined significantly to ₹220.24 crore from ₹360.22 crore YoY. The continuing Income Tax Department matter disclosed in the filing may also have added to investor caution. The company said assessment orders for AY2014-15 to AY2023-24 had been issued and appeals were filed against them, though management stated it does not expect any material liability. Overall, while Yatharth Hospital delivered strong revenue growth and healthy headline PAT numbers, the Street appears to have focused more on declining operating efficiency, rising costs, heavy capex commitments, and execution risks associated with multiple simultaneous hospital expansions. Disclaimer: This article is for informational purposes only and does not constitute investment advice.
JPMorgan downgrades LTM stock, cuts target price after Randstad Europe deal announcement — stock falls
LTM shares slipped intraday after JPMorgan downgraded the stock and cut its target price following the company’s proposed Randstad Europe acquisition.
Sammaan Capital Lost ₹8,101 Crore in Q4. So Why Is the Stock Up 20% in 5 Days?
Sammaan Capital reported an ₹8,101 crore Q4 FY26 loss yet its stock surged 20% in 5 days. The IHC investment, AA+ rating upgrade, and zero NPA story explain why. Full analysis.
Here’s what got the street excited about Eicher Motors’ Q4 results as stock surges 6%
Eicher Motors shares rallied over 5% after Q4FY26 results beat analysts estimates. Brokerages remain positive on Royal Enfield demand, margins and capacity expansion.
Why are HPCL, BPCL share prices up over 5% today? Explained
HPCL, BPCL and IOC shares rallied up to 6% on Monday after crude oil prices dropped sharply amid hopes of a US-Iran peace agreement and easing Strait of Hormuz tensions.
Weak Q4 results drag Jubilant Pharmova shares nearly 4% from day’s high
Jubilant Pharmova shares came under pressure on Friday after the company reported a mixed set of Q4FY26 earnings, with profitability and margins declining despite strong revenue growth. The stock fell nearly 3.9% from its intraday high of ₹1,025 to a low of ₹988 during the session. At around 2:41 PM, the stock was trading at ₹1,005, down 0.66% for the day. The pharmaceutical company reported a 23% year-on-year decline in net profit to ₹119 crore for the quarter ended March 2026, compared to ₹154 crore in the corresponding quarter last year. Revenue from operations, however, rose 18.8% YoY to ₹2,290 crore against ₹1,928 crore in Q4FY25, indicating healthy business momentum across segments. EBITDA for the quarter came in at ₹339.3 crore, marginally lower by 1.6% compared to ₹345 crore a year ago. EBITDA margin contracted sharply to 14.8% from 17.9% in the year-ago period, reflecting pressure on operating profitability despite higher sales growth. The market reaction appeared to be driven primarily by the margin compression and decline in earnings, even as topline growth remained strong. Investors also tracked the sharp difference between revenue expansion and operating profit trends, which pointed toward higher costs impacting profitability during the quarter. On the stock-specific front, Jubilant Pharmova touched an intraday high of ₹1,025 before witnessing selling pressure. The stock moved within a broad range of ₹988–₹1,025 during the session, while trading volumes crossed 4.24 lakh shares. Jubilant Pharmova operates across pharmaceuticals, radiopharma, contract research and development services, allergy therapy and drug discovery solutions, with business presence across domestic and global markets. Disclaimer: This article is based on company earnings updates and market data. It is intended for informational purposes only and should not be construed as investment advice.
Electronics Mart stock rallies as Q4 profit rises 49%, NCR growth stays strong
Shares of Electronics Mart India Ltd rallied nearly 8% in Friday’s trade after the company posted a strong set of Q4FY26 numbers, aided by healthy demand across categories, improving operating leverage and continued expansion across key markets. The company reported consolidated revenue from operations of ₹1,913 crore for the March quarter, registering a 15% year-on-year growth, while profit after tax surged 49% YoY to ₹40 crore. EBITDA came in at ₹129 crore, up 20% from the year-ago quarter, with EBITDA margin expanding 30 basis points to 6.7%. Electronics Mart said the quarter witnessed double-digit growth across all product categories despite price hikes in larger appliances, while its core clusters continued to deliver steady growth. The company also highlighted margin improvement driven by operating leverage. Operational metrics remained robust during the quarter. Same store sales growth stood at 12.1%, while bill cuts rose 19.5% YoY to 785,000. Average ticket size increased to ₹23,287. The company opened four net new stores during Q4FY26. The company’s NCR business continued to scale up rapidly. Revenue from the Delhi NCR cluster jumped 31% YoY to ₹148 crore during Q4FY26, while same-store sales growth in the region stood at 18.6%, the highest among all clusters. Management also highlighted that the North cluster, where operations began in 2022, is being scaled aggressively using the same cluster-based strategy that helped the company dominate southern markets. The company expects store productivity and margins in the North to gradually align with South cluster benchmarks as scale improves. During FY26, Electronics Mart added 23 net stores, taking its total retail footprint to 223 stores across 95 cities and six states, with a retail area exceeding 1.94 million sq ft. The company also used the investor presentation to emphasise its premium positioning strategy and partnerships with global consumer electronics brands including Apple, Sony, LG, Samsung, Oppo, Vivo, Bosch and Whirlpool. It said its average selling price has risen 19% from FY20 levels to ₹23,125 in FY26, reflecting increasing premiumisation trends. Electronics Mart further noted that mature stores older than four years generated EBITDA margins of 7.3% during FY26, compared with 3.1% for newer stores, indicating scope for profitability improvement as recently opened outlets mature. The company also reported strong cash flow generation, with operating cash flow rising to ₹444 crore in FY26 from ₹176 crore in FY25. Disclaimer: This article is based on company filings and investor presentation details. Investors are advised to consult certified financial advisors before making investment decisions.
What led to the 3% fall in GSFC shares today? Explained
Shares of Gujarat State Fertilizers & Chemicals Ltd (GSFC) fell over 3% in Friday’s trade after the company reported a decline in quarterly profitability and margin compression in its Q4FY26 results. The stock dropped as much as 3.15% to ₹169.20 on the NSE against the previous close of ₹174.70. The counter also witnessed active trading volumes during the session. For Q4FY26, GSFC reported net profit of ₹52 crore, down 27.5% year-on-year from ₹71.7 crore in the corresponding quarter last year. Despite the decline in profit, revenue from operations rose sharply by 37% YoY to ₹2,632.7 crore compared to ₹1,922.2 crore in Q4FY25, indicating stronger topline growth. Operationally, EBITDA increased marginally by 4% year-on-year to ₹83.2 crore from ₹80 crore. However, EBITDA margin declined to 3.2% from 4.2% in the year-ago period, reflecting pressure on profitability despite higher revenues. The margin compression appears to have weighed on investor sentiment, as markets often closely track operational profitability trends in commodity-linked businesses such as fertilisers and chemicals. A lower EBITDA margin generally indicates that cost increases or weaker pricing power offset part of the revenue growth, reducing operating efficiency. In cyclical sectors like chemicals and fertilisers, margins are influenced by factors such as raw material prices, energy costs, subsidy dynamics and product realisations. The decline in net profit despite higher revenues also suggests that earnings growth lagged topline expansion during the quarter. GSFC operates across fertilisers, industrial chemicals and petrochemical products, and remains one of India’s major integrated fertiliser and chemical manufacturers. Disclaimer: This article is based on company-reported financial figures and market data. Investors are advised to consult certified financial advisors before making investment decisions.
Naukri parent Info Edge shares jump 6% after strong Q4 margin expansion
Shares of Info Edge (India) Ltd, the parent company of Naukri, surged over 5% in Friday’s trade after the company reported strong Q4FY26 results marked by healthy revenue growth, sharp margin expansion and robust cash generation. The stock climbed as much as 6.1% intraday to ₹982.95 on the NSE before trading around ₹978.20, up 5.61% from the previous close. The counter also witnessed elevated trading activity, with over 26 lakh shares changing hands during the session. The rally came after the company reported standalone revenue from operations of ₹805.1 crore for Q4FY26, registering a 17.2% year-on-year increase. Operating profit for the quarter rose 39.4% YoY to ₹322.7 crore, while operating margin expanded sharply to 40.1%. On a sequential basis, EBITDA margin improved to 38.4% from 35.92% in the previous quarter. At the consolidated level, net sales stood at ₹869 crore in Q4FY26 compared to ₹749.6 crore in the year-ago period. Profit before tax, excluding exceptional items, came in at ₹798.5 crore versus ₹716.1 crore last year. The company also continued to generate strong cash flows, with standalone cash from operations before taxes reaching ₹621.1 crore during the quarter. Investors also tracked the performance of the recruitment business, which remains Info Edge’s largest vertical. Recruitment business billings stood at ₹811 crore in Q4FY26, while operating profit came in at ₹340 crore with operating margins of 58.5%. Naukri maintained strong platform metrics during the quarter, including over 115 million resumes in its database and around 666,000 active job listings. Management commentary also remained constructive. Managing Director and CEO Hitesh Oberoi said the company witnessed improving operating margins during FY26, especially in the recruitment business, while continuing to deepen AI integration across matching, recommendations and new AI-native products. The company further noted that 99acres and Jeevansathi continued gaining market share during the year. Despite the sharp recovery in Friday’s session, the stock still remains below its 52-week high of ₹1,550. Disclaimer: This article is based on company filings, management commentary and market data. Investors are advised to consult certified financial advisors before making investment decisions.
Here’s what the street cheered about Honasa Consumer’s Q4 results and what analysts say
Honasa Consumer shares surged over 6% today after the company delivered a strong Q4FY26 performance that exceeded Street expectations on both growth and profitability fronts. The stock climbed as much as 10.4% intraday to hit a fresh 52-week high of ₹398 on the NSE before trimming gains. At around 11:13 AM, the stock was trading 6.19% higher at ₹382.80. The rally followed Honasa Consumer’s robust March quarter earnings , where the company reported 28% year-on-year revenue growth to ₹682 crore, while EBITDA and PAT more than doubled. The company also announced its maiden final dividend of ₹3 per equity share. Brokerages highlighted three major positives from the quarter — improving growth in the flagship Mamaearth brand, continued momentum in younger brands and sharp margin expansion driven by operating leverage. CLSA maintained its “Outperform” rating on the stock with a target price of ₹434. The brokerage said Honasa reported revenue growth of 23% YoY, or 28% excluding accounting changes, which was ahead of both its estimates and Street consensus. According to CLSA, volume growth stood at 30%, while EBITDA margin expanded by over 650 basis points year-on-year, leading to EBITDA beating estimates by a wide margin. The brokerage noted that Mamaearth returned to mid-teen growth and management expects double-digit momentum to continue. CLSA also pointed to strong offtake growth of around 30% YoY across general trade and modern trade channels, indicating improving brand traction. Another key positive highlighted by CLSA was the operating leverage-led profitability improvement, with EBITDA margin exceeding expectations by over 140 basis points. The brokerage said it remains constructive on Honasa’s long-term brand scaling opportunity across focus categories and hero SKUs. Jefferies also reiterated its “Buy” rating on the stock and assigned a target price of ₹565. The brokerage said Honasa appears to have moved past its most challenging phase related to distribution realignment and is now firmly back on a strong growth trajectory. Jefferies highlighted that the fourth quarter showed improving performance across the board, including mid-teen growth in Mamaearth, continued strong momentum in younger brands and record-high margins. The brokerage added that management’s guidance of high-teen revenue growth along with annual EBITDA margin expansion of around 100 basis points strengthens the long-term compounding narrative for the company. Management commentary also remained optimistic, with the company saying its investments in AI-led content systems, innovation and offline distribution are beginning to translate into stronger execution quality and sustained profitable growth. Disclaimer: This article is based on brokerage reports, company commentary and market data. Investors are advised to consult certified financial advisors before making investment decisions.
Here’s why Aurobindo Pharma fell over 5% today despite good profit and revenue growth in Q4
Aurobindo Pharma shares fell over 5% in Friday’s trade after the company reported a muted operational performance for Q4FY26, with weakness in the key US business and margin pressure weighing on investor sentiment. The stock declined as much as 5.02% to ₹1,469.10 on the NSE against the previous close of ₹1,546.70. The stock also slipped from its 52-week high of ₹1,550 touched recently. For Q4FY26, Aurobindo Pharma reported consolidated revenue of ₹8,853 crore, up 5.6% year-on-year. EBITDA stood at ₹1,801 crore, rising marginally by 0.5% YoY, while EBITDA margin declined 110 basis points to 20.3%. Net profit for the quarter came in at ₹921 crore, up 2% YoY. Investor concerns largely centred around the company’s US formulations business, which declined 13% year-on-year during the quarter. Management attributed the fall to seasonality and lower transient product sales in the US market, which remains the company’s largest geography. On the other hand, Europe business posted strong growth of 30.2% YoY, while the Non Beta-lactam API segment surged 55.4% YoY, partly offsetting weakness in the US operations. The company also highlighted ongoing strategic investments, including the acquisition of Khandelwal Labs’ non-oncology business for US$32 million and planned capital expenditure of US$150-175 million towards a new biologics facility under TheraNym. During the earnings call, management said it expects EBITDA margin to improve to above 21% in FY27 and indicated that US formulations revenue could reach around US$2 billion over the next couple of years. Aurobindo Pharma also said a key biosimilar candidate, Omalizumab, met all primary endpoints in Phase 3 trials, paving the way for regulatory filings. As of March 31, 2026, the company maintained a net cash balance of US$317 million. Disclaimer: This article is based on company-reported financial figures, management commentary and market data. Investors are advised to consult certified financial advisors before making investment decisions.
Manali Petrochemicals shares jump 13% after strong Q4 earnings boost sentiment
Manali Petrochemicals shares surged 13% after the company reported strong Q4 FY26 earnings with higher revenue and profit growth.
Here’s why WeWork shares jumped over 7% in trade today
WeWork India shares surged over 7% in Thursday’s trade after the company reported a sharp rise in profit and revenue for the fourth quarter of FY26, supported by strong operational performance and sustained demand for managed office spaces. The stock climbed as much as 7% intraday after the company announced its quarterly earnings, with investors reacting positively to the improvement in profitability and steady margin performance. For Q4FY26, the company reported net profit of ₹65 crore, marking a 78% year-on-year increase from ₹37 crore reported in the corresponding quarter last year. Revenue from operations rose 27% YoY to ₹705 crore compared to ₹555 crore in Q4FY25, reflecting continued momentum in enterprise demand and workspace occupancy trends. EBITDA for the quarter increased 28% YoY to ₹459 crore from ₹360 crore a year ago, while EBITDA margin remained largely stable at 65.1% versus 64.9% in the year-ago period. The earnings performance comes amid growing demand for flexible workspaces across major Indian cities as companies increasingly adopt hybrid work models and managed office solutions. Market participants also tracked the company’s improving profitability trajectory and operational scale, which helped support investor sentiment during the session. WeWork India operates flexible workspace centres across key commercial hubs and caters to enterprises, startups and hybrid workforce requirements. Disclaimer: This article is for informational purposes only and should not be construed as investment advice.
Here’s what got the street excited about JSW Cement as stock rallies 6% today
Shares of JSW Cement rallied more than 6% in trade on May 21 after the company reported a sharp improvement in quarterly profitability and a strong jump in operating margins, boosting investor sentiment around the cement maker’s earnings trajectory. The stock climbed as much as 6% intraday to ₹132.13 on the NSE, compared with the previous close of ₹120.91. At around 12:08 PM, the stock was trading near ₹127.46, up 5.4% for the day. Trading volumes also remained robust, with more than 63 lakh shares changing hands on the exchange. The rally came after JSW Cement posted a significant rise in Q4 FY26 earnings, led by margin expansion and a sharp increase in net profit. Strong margin expansion drives optimism For the March 2026 quarter, JSW Cement reported revenue from operations of ₹1,894.99 crore, up 10.9% year-on-year from ₹1,709.39 crore. Operational performance improved sharply during the quarter. EBITDA surged to ₹364.1 crore compared with ₹240.2 crore reported in the corresponding quarter last year, reflecting a growth of over 51%. More importantly, EBITDA margin expanded significantly to 19.2% from 14.1% a year ago, indicating improved operational efficiency and better cost management despite industry-wide cost pressures. The company’s consolidated net profit jumped to ₹361.65 crore in Q4 FY26 from ₹16.21 crore reported in Q4 FY25. Profit before tax also rose sharply to ₹214.88 crore compared with ₹75.75 crore in the year-ago period. Street cheers operational turnaround Market participants appeared encouraged by the strong profitability improvement, especially as the cement sector continues to navigate pricing volatility and cost pressures. Investors also reacted positively to the company’s stronger operating leverage, with EBITDA growth significantly outpacing revenue growth during the quarter. For the full financial year FY26, JSW Cement reported revenue from operations of ₹6,512.46 crore, compared with ₹5,813.07 crore in FY25. However, the company reported a consolidated loss of ₹798.78 crore for FY26 due to exceptional items amounting to ₹1,504.48 crore during the year. Despite the annual loss, the market focus remained firmly on the sharp sequential and year-on-year improvement in quarterly profitability and operating metrics. Disclaimer: This article is based on market data and company filings. It does not constitute investment advice.
Why are Sammaan Capital shares up over 8% today despite a huge loss in Q4? Explained
Sammaan Capital (formerly Indiabulls Housing Finance) staged a sharp 9% rally to ₹154 on the NSE on Thursday morning — even as the company reported one of the largest quarterly losses in its history. The apparent paradox has a clear explanation: the market is looking past the headline numbers. Sammaan Capital reported a consolidated net loss of ₹8,101 crore for Q4 FY26, compared with a profit of ₹324 crore in the same quarter last year. Total income for the quarter fell 36% year-on-year to ₹1,361 crore from ₹2,132 crore. The loss, however, is largely non-cash and one-time in nature. The company recognised an exceptional loss of ₹6,499 crore linked to the sale of non-core legacy loan exposures to an asset reconstruction company. Management clarified this was done to transfer collection responsibilities to an external agency — not because of fresh asset quality stress — freeing management to focus on scaling new business lines under the IHC framework. The NBFC however is also looking to enter the gold lending business, a category which has seen an enormous rise ovet the past few quarters amid rising gold prices. The real story is the transformation underway. Abu Dhabi-based International Holding Company (IHC) has been classified as promoter, with a total committed investment of ₹8,850 crore — one of the largest FDIs in India’s NBFC sector — currently holding 28.41% equity with a path to 41.24% on a fully diluted basis. The strategic vote of confidence has triggered a credit rating sweep. Within 50 days of IHC’s investment, all three major domestic agencies — CRISIL, CARE, and ICRA — upgraded Sammaan Capital to AA+/Stable. Lower cost of funds and a diversified product roadmap including gold loans and unsecured business loans are now squarely in sight. For investors, the Q4 loss is a balance sheet reset, not a distress signal.
Why is Jubilant Foodworks share price down over 7% today? Here’s what got the street disappointed
Shares of Jubilant FoodWorks Ltd came under heavy selling pressure in early trade on May 21 after multiple brokerages turned cautious on the stock following the company’s Q4 FY26 earnings and management commentary. The stock fell nearly 7% to an intraday low of ₹438.60 on the NSE, while trading around ₹439.80 at 9:20 AM, compared with the previous close of ₹472.55. The stock opened lower at ₹449.30 and remained under pressure throughout the morning session. Volumes also remained elevated, with over 14.8 lakh shares changing hands. The sharp decline follows target price cuts and cautious commentary from global brokerages including HSBC and Jefferies, which flagged weak same-store sales growth trends, moderation in demand momentum and near-term margin pressures. HSBC downgrades stock to ‘Hold’ HSBC downgraded Jubilant FoodWorks to ‘Hold’ and maintained its target price at ₹530. The brokerage highlighted that like-for-like (LFL) growth of just 0.2% during Q4 marked a sharp moderation in demand trends. According to HSBC, the quarter did not benefit from any major one-off gains, apart from a marginal LPG-related impact of around 0.3-0.4%. The brokerage also noted that early Q1 trends appear slightly better but are largely driven by activations and promotional efforts, raising concerns around the balance between growth and profitability. HSBC further warned that inflationary pressures may remain a near-term headwind and said it has cut estimates for the company. Jefferies slashes target price by ₹250 Jefferies retained its ‘Buy’ rating on Jubilant FoodWorks but sharply reduced its target price to ₹600 from ₹850 earlier. The brokerage said flat same-store sales growth and cautious short-term margin commentary indicate that a meaningful turnaround may still take time. It added that consumer technology platforms are increasingly becoming preferred investment plays within the broader consumption theme, limiting enthusiasm for the stock. While Jefferies acknowledged that Q4 earnings modestly beat its estimates, it said management’s calibrated pricing strategy could lead to a 10-12% cut in EBITDA estimates going forward. Q4 results snapshot Jubilant FoodWorks reported consolidated revenue from operations of ₹2,499.47 crore in Q4 FY26, up 19.3% year-on-year from ₹2,095.02 crore. Net profit rose sharply to ₹824.23 crore compared with ₹493.30 crore reported in the year-ago quarter. EBITDA stood at ₹484.9 crore against ₹391.9 crore in Q4 FY25, while EBITDA margin improved to 19.4% from 18.7%, expanding by 70 basis points year-on-year. Despite the strong headline numbers, analysts remain cautious on the demand outlook, especially around dine-in trends, same-store sales growth and the company’s ability to sustain margins amid inflationary pressures and competitive intensity. Disclaimer: This article is based on brokerage reports, market data and company filings. Brokerage views mentioned are their own and do not represent the views of the publication. This article does not constitute investment advice.
Here’s what the street liked about Mankind Pharma’s Q4 results as stock surges 4% today
Shares of Mankind Pharma gained over 3% in early trade on May 20 after the company reported strong March quarter earnings, supported by healthy domestic business growth, improving margins and strong traction in its consumer healthcare portfolio. The stock was trading at ₹2,570.60 on the NSE, up 3.13%, after touching an intraday high of ₹2,579.50. The rally also pushed the stock closer to its 52-week high of ₹2,716.50. For Q4FY26, Mankind Pharma reported revenue of ₹3,443 crore, compared to ₹3,079 crore in the year-ago period, registering an 11.8% growth. Net profit rose 31.7% year-on-year to ₹559 crore from ₹425 crore, while EBITDA jumped 36.1% to ₹930 crore from ₹683 crore in the corresponding quarter last year. The company’s EBITDA margin expanded sharply to 27% from 22.2% a year ago, indicating strong operating leverage and improved product mix. Brokerage firm Morgan Stanley maintained its “Overweight” rating on the stock with a target price of ₹2,500. The brokerage highlighted that EBITDA growth was driven by healthy domestic business performance and strong execution across key therapy segments. According to the brokerage, Mankind continued to witness healthy double-digit domestic growth, backed by robust performance in major therapies. The domestic business grew 13% year-on-year during Q4FY26, driven by strong growth in the core Mankind franchise. The cardiac segment recorded 14.7% growth, while the anti-diabetes segment grew 11.6%. The chronic portfolio contribution also increased to nearly 40%, reflecting improving portfolio quality. The company’s consumer healthcare or OTC business also remained a key highlight during the quarter. Revenue from the segment grew 20% YoY, led by strong demand for brands such as Manforce, Prega News and Gasofast. Mankind also saw rising contribution from digital channels, with e-commerce and modern trade share increasing to 13% in FY26. Its specialty business under Bharat Serums and Vaccines (BSV) posted healthy growth in key brands including Foligraf, which grew 52%, and HMG, which rose 40%. Meanwhile, the international business reported relatively muted growth of 4% year-on-year during the quarter, impacted by geopolitical headwinds. Apart from the earnings performance, the board also approved an investment of up to ₹500 crore in subsidiary Mankind Medicare and reappointed Satish K Sharma as Whole-Time Director for five years. Disclaimer: This article is for informational purposes only and should not be construed as investment advice.
Why are Hindalco shares up nearly 4% today? Explained
Shares of Hindalco Industries gained nearly 4% in early trade on May 20 after investors reacted positively to the March quarter performance and outlook commentary of its subsidiary Novelis, despite concerns around higher debt levels and the financial impact of the Oswego plant fire. Hindalco shares were trading at ₹1,085.60, up 3.56% on the NSE, after touching an intraday high of ₹1,089.50. The stock also moved close to its 52-week high of ₹1,105 during the session. Novelis, the aluminium rolling and recycling major owned by Hindalco, reported Q4FY26 adjusted EBITDA per tonne of $544, compared to $494 in the year-ago period. The company said profitability was impacted by the Oswego facility fire incident and tariff-related pressures, though insurance recoveries linked to flooding at the Sierre facility provided some support. Shipments during the quarter declined 12% year-on-year to 844 kilo tonnes. While operational performance remained resilient, investors continued to monitor a few key concerns highlighted in the update. Novelis estimated the fire-related free cash flow impact at nearly $1.7 billion before insurance recoveries, higher than its earlier estimate range of $1.3–1.6 billion. The company’s leverage also rose during the quarter, with net debt-to-EBITDA increasing to 4.1x, the highest level seen in nearly 23 quarters. Net debt rose 8% sequentially to $6.8 billion. Despite the near-term concerns, management maintained its broader guidance and long-term outlook, which appeared to support investor sentiment. Novelis reiterated that it expects to turn free cash flow positive by the end of FY27. The company also said the restart of its New York plant is expected in the coming weeks. In addition, the much-tracked Bay Minette project remains on schedule for completion by the end of calendar year 2026, reinforcing confidence around future growth capacity and downstream aluminium demand. Analysts have been closely watching Novelis’ execution amid global aluminium demand trends, tariff-related uncertainties and the impact of operational disruptions. However, the reaffirmation of guidance and improving profitability metrics appear to have overshadowed concerns around leverage and temporary disruptions in the latest trading session. Disclaimer: This article is for informational purposes only and should not be construed as investment advice.
Why are Zydus Life shares up another 6% today? Here’s what led the rally
Zydus Life Sciences shares surged nearly 6% in early trade on Wednesday, extending gains after the company’s post-results management commentary boosted investor sentiment. The stock rose as much as 5.8% to ₹1,078.75, a fresh 52-week high, before trading around ₹1,077.80 on the NSE. The rally came after the management outlined a strong growth outlook for FY27 during its earnings concall. The company guided for a US revenue base of over $300 million per quarter and projected single-digit growth in the US business during FY27. Zydus Life estimated its FY27 US revenues in the range of $1.3–1.4 billion. Management also indicated that the India business is expected to maintain growth momentum, supported by the oncology portfolio and upcoming GLP-1 opportunities. The international business is projected to grow 40–45% in FY27, reflecting strong traction in global markets. Investor sentiment was further supported by the company’s recently announced buyback proposal. Zydus Life approved a share buyback worth ₹1,100 crore through the tender offer route at a price of ₹1,150 per share. The company plans to buy back up to 95,65,217 equity shares, with May 29, 2026 fixed as the record date. Based on the earlier prevailing market price of around ₹1,020, the buyback price implied a premium of nearly 12.7%. The company also reported a strong operational performance for Q4 FY26. Net profit rose to ₹1,272.5 crore from ₹1,170.9 crore in the year-ago quarter, while revenue from operations increased to ₹7,587 crore from ₹6,527.9 crore YoY. EBITDA came in at ₹2,554 crore compared to ₹2,125.5 crore a year ago, while EBITDA margin improved to 33.7% from 32.6%. Earnings per share stood at ₹12.65 versus ₹11.64 YoY. The upbeat FY27 guidance, healthy quarterly performance and buyback announcement have together lifted investor confidence in the stock, helping Zydus Life extend its recent rally. Disclaimer: This article is for informational purposes only and should not be construed as investment advice.
Why did Dhanuka Agritech share price jump nearly 10% today? Explained
Dhanuka Agritech Limited shares surged nearly 10% in Tuesday’s trade after the company announced a share buyback plan alongside a strong set of Q4FY26 earnings. The stock rose as much as 10% intraday after the board approved a buyback of up to 1.11% of the company’s equity shares at ₹1,400 per share , representing an approximate 18% premium to the prevailing market price. Investor sentiment was further supported by healthy quarterly earnings growth. Dhanuka Agritech reported a net profit of ₹98 crore for Q4FY26, up 30% from ₹76 crore in the corresponding quarter last year. Revenue from operations increased 9% YoY to ₹483 crore compared to ₹442 crore in Q4FY25. EBITDA rose 14% YoY to ₹124 crore against ₹109 crore in the year-ago quarter. The company also reported margin expansion during the quarter, with EBITDA margin improving to 25.7% from 24.7% YoY, reflecting better operational performance. Following the announcements, Dhanuka Agritech shares traded around ₹1,177, up over 8% during the session, after hitting an intraday high of ₹1,200. The buyback announcement is being viewed positively by investors as it signals management confidence in the company’s long-term outlook while also enhancing shareholder value through a premium offer price. Disclaimer: This article is for informational purposes only and does not constitute investment advice.
Why Jain Resource Recycling shares fell 15% today?
Shares of Jain Resource Recycling fell sharply on May 19 , extending their decline to nearly 30% since the company’s results , as investors focused on weak operating cash flow and rising working capital pressure despite strong revenue and profit growth. The stock was trading at Rs 396.05 , down 14.54% or Rs 67.40 on the NSE. During the session, the stock moved in a wide range of Rs 378.00 to Rs 452.95 . The previous close stood at Rs 463.45 . The company reported strong FY26 numbers on the surface. Consolidated revenue from operations rose 48% to Rs 9,543 crore , while annual net profit increased nearly 59% to around Rs 352 crore . Q4 FY26 revenue also grew 76% year-on-year to Rs 3,100 crore , compared with Rs 1,760 crore in Q4 FY25. Net profit rose 15% to Rs 60.4 crore from Rs 52.4 crore a year earlier. However, the market reaction was driven by concerns over cash generation. Despite reporting profit of around Rs 352 crore for FY26, the company reported negative operating cash flow of Rs 602 crore . This gap between accounting profit and actual cash generation became the key concern for investors. The pressure was visible in working capital. Trade receivables rose sharply from Rs 129 crore to Rs 476 crore , while inventory increased from Rs 675 crore to Rs 1,477 crore . Both receivables and inventory grew much faster than revenue, indicating that a large part of growth was locked in working capital. To fund this expansion, short-term borrowings increased from Rs 916 crore to Rs 1,271 crore . This suggested that growth was being supported by debt rather than internal operating cash generation. Segmentally, the growth remained strong. Copper revenue rose 65% to Rs 5,262 crore , while copper segment profit increased 85% to Rs 194 crore . Lead revenue rose 36% to Rs 3,818 crore , making it a key cash-generating business. However, valuations remained demanding. At elevated multiples, the market was pricing in strong execution, steady cash conversion and clean working capital management. The negative operating cash flow weakened that assumption. The company has also announced plans to set up a new plastic recycling facility with an estimated capex of Rs 15 crore , expected to become operational by Q3 FY27 . Overall, Jain Resource Recycling shares fell because investors looked beyond headline revenue and profit growth and focused on the sharp rise in receivables, inventory build-up, higher short-term borrowings and negative operating cash flow. The key number to watch in the next quarter will be operating cash flow. If it turns positive, the growth story may stabilise; if it remains negative, concerns around working capital intensity may continue. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions.